- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05030155
Étude du régime à base de mépolizumab par rapport à la stratégie thérapeutique conventionnelle chez des patients atteints de granulomatose à éosinophiles avec polyangéite (E-merge) (E-merge)
Évaluation du régime à base de MEpolizumab par rapport à la stratégie thérapeutique conventionnelle pour l'induction de la rémission chez les patients atteints de granulomatose éosinophile avec polyangéite. Étude prospective, randomisée, contrôlée, en double aveugle
The purpose of this study is to compare mepolizumab-based regimen to conventional therapeutic strategy for remission induction in patients with Eosinophilic Granulomatosis with Polyangiitis.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called Churg-Strauss syndrome, is a rare systemic small-vessel vasculitis, associated with asthma and blood and tissue eosinophilia. EGPA belongs to the group of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV), and commonly involves upper and lower respiratory tracts, the lungs, the peripheral nerve and the heart.
Therapeutic management is based on glucocorticoids alone or in combination with conventional immunosuppressive agents, mainly azathioprine, methotrexate or cyclophosphamide, according to disease severity assessed by the Five Factor Score.
Such treatments, in addition to their common side effects, are frequently insufficiently effective to control chronic asthma and/or rhinosinusitis, requiring long-term high-dose corticosteroids. Because EGPA shares common pathophysiological features with eosinophilic disorders and asthma, new therapeutic options used in these conditions could be of interest, in particular mepolizumab, a monoclonal anti-interleukin (IL)-5 antibody, which has shown promising results in two small preliminary studies to control disease activity and decrease glucocorticoids in cortico-dependant patients. In addition, mepolizumab has been recently evaluated in a prospective trial, the MIRRA trial, targeting a small niche of patients, i.e. those with corticodependent asthma unable to achieve disease control with low dose of glucocorticoids. Results published revealed that mepolizumab led to significantly more accrued weeks of remission than placebo (28% vs. 3% of the participants had ≥24 weeks of accrued remission; odds ratio, 5.91; 95% confidence interval [CI], 2.68 to 13.03; P<0.001) and a higher percentage of participants in remission at both week 36 and week 48 (32% vs. 3%; odds ratio, 16.74; 95% CI, 3.61 to 77.56; P<0.001).
However, these studies did not evaluate the interest of mepolizumab during EGPA flare associating asthma, eosinophilic and vasculitis lesions, in order to induce remission of the disease and rapidly decrease and discontinue glucocorticoids.
Also, recent pathophysiological date strongly support in addition to previous therapeutic studies the major interest to target IL-5 as soon as EGPA is diagnosed: 1) genetic association studies demonstrated that polymorphisms in the IL-5 pathway are associated with EGPA in comparison with controls, 2) increased expression of IL-5 in mice model are able to induce vasculitis lesions as observed in the human diseases.
Patients will receive a standardized glucocorticoid tapering schedule. From day 28 post-baseline onwards, if the subject's BVAS=0 their oral prednisone dose should be tapered downwards. A standardized glucocorticoid tapering schedule provided in the protocol enables a reduction in oral prednisone dose every 2 weeks, with the intention of achieving a prednisone dose of 4 mg/day or less. Once a subject has achieved a dose of 4 mg/day prednisone, the investigator is encouraged to continue tapering downwards, if clinically warranted, at dose increments of 1.0 mg every week.
Upwards dose adjustments within the 0-4.0 mg range are permitted without necessarily being considered a relapse.
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Paris, France, 75014
- Service de Médecine Interne, Centre de référence " Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques "Hôpital Cochin
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients with a diagnosis of EGPA independently of ANCA status,
- Patients aged of 18 years or older,
- Patients with newly-diagnosed disease or relapsing disease at the time of screening, with an active disease defined as a Birmingham Vasculitis Activity Score (BVAS) ≥3,
- Patients within the first 21 days following initiation/increase of corticosteroids at a dose ≤ 1 mg/kg/day (pulses of methylprednisolone before oral corticosteroid therapy are authorized)
- Patients having given their written informed consent prior to participation in the study.
- Patients affiliated with social security or CMU (profit or being entitled)
Exclusion Criteria:
- Patients with GPA, MPA, or other vasculitis, defined by the ACR criteria and/or the Chapel Hill Consensus Conference,
- Patients with vasculitis in remission of the disease defined as a BVAS <3
- Patients with severe cardiac failure defined as class IV in New York Heart Association
- Patients with acute infections or chronic active infections (including HIV, HBV or HCV and checked in the last 12 months),
- Patients with active cancer or recent cancer (<5 years), except basocellular carcinoma and prostatic cancer of low activity controlled by hormonal treatment,
- Pregnant women and lactation. Patients with childbearing potential should have reliable contraception for the 12 months duration of the study,
- Patients with EGPA who have already been treated with mepolizumab within the previous 12 months,
- Patients with hypersensitivity to a monoclonal antibody or biologic agent,
- Patients with contraindication to use mepolizumab, cyclophosphamide, mesna, azathioprine or maintenance therapy used for vasculitis,
- Patients with other uncontrolled diseases, including drug or alcohol abuse, severe psychiatric diseases, that could interfere with participation in the trial according to the protocol,
- Patients included in other investigational therapeutic study within the previous 3 months,
- Patients suspected not to be observant to the proposed treatments,
- Patients who have white blood cell count ≤4,000/mm3,
- Patients who have platelet count ≤100,000/mm3,
- Patients who have ALT or AST level greater that 3 times the upper limit of normal that cannot be attributed to underlying EGPA disease,
- Patients unable to give written informed consent prior to participation in the study
- Patients under tutorship or curatorship and protected adults.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Patients with FFS=0 - Mepolizumab
Mepolizumab 300mg every 4 weeks until D336 |
300 mg/month subcutaneous |
|
Comparateur placebo: Patients with FFS=0 - Placebo
Placebo of Mepolizumab every 4 weeks until D336 |
Patients with FFS=0 will receive placebo |
|
Expérimental: Patients with FFS≥1 - Mepolizumab
Mepolizumab 300mg every 4 weeks until D336 and placebo of Azathioprine 1mg/kg/day from D126 until D360 and placebo of cyclophosphamide/mesna at D1, D15, D28, D56, D84 and D112 |
300 mg/month subcutaneous Patients with FFS=0 will receive placebo |
|
Comparateur placebo: Patients with FFS≥1 - Placebo
Placebo of Mepolizumab every 4 weeks until D336, cyclophosphamide and mesna at D1, D15, D28, D56, D84 and D112 and Azathioprine 1mg/kg/day from D126 until D360 |
Patients with FFS=0 will receive placebo Patients with FFS≥1 will receive cyclophosphamide then azathioprine |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of patients who achieved a prednisone dose of 4.0 mg or less per day at day 168, without experiencing a relapse
Délai: Day 168
|
EGPA relapse will be defined as worsening or persistence of active disease since the last visit characterized by: a) active vasculitis (BVAS >0); OR b) active asthma symptoms; OR c) active nasal and/or sinus disease, warranting: i) an increased dose of prednisone compared to previous dosage and at least >4 mg/day prednisone total daily dose or equivalent; OR ii) an increased dose or addition of immunosuppressive therapy; OR iii) hospitalisation related to EGPA worsening. A BVAS evaluation will be conducted at the time of a relapse, or as soon as possible afterwards |
Day 168
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Dosage de la prednisone aux jours 168 et 364
Délai: Jours 168 et 364
|
Jours 168 et 364
|
|
|
Aire sous la courbe des corticostéroïdes aux jours 168 et 364
Délai: Jours 168 et 364
|
Jours 168 et 364
|
|
|
Proportion de participants ayant reçu une dose de prednisone de 4,0 mg ou moins par jour pendant 0 semaine
Délai: Jours 168 et 364
|
Jours 168 et 364
|
|
|
Proportion de participants ayant reçu une dose de prednisone de 4,0 mg ou moins par jour pendant plus de 0 semaine mais moins de 4 semaines
Délai: Jours 168 et 364
|
Jours 168 et 364
|
|
|
Proportion de participants ayant reçu une dose de prednisone de 4,0 mg ou moins par jour pendant plus de 4 semaines mais moins de 12 semaines
Délai: Jours 168 et 364
|
Jours 168 et 364
|
|
|
Proportion de participants ayant reçu une dose de prednisone de 4,0 mg ou moins par jour pendant au moins 12 semaines
Délai: Jours 168 et 364
|
Jours 168 et 364
|
|
|
Proportion de participants ayant reçu une dose de prednisone de 4,0 mg ou moins par jour aux jours 168 et 364.
Délai: Jour 364
|
Jour 364
|
|
|
Délai entre l'inclusion et la première rechute
Délai: Jour 364
|
Jour 364
|
|
|
Indice de dommages de la vascularite (VDI)
Délai: Jours 168 et 364
|
Jours 168 et 364
|
|
|
Questionnaire HAQ
Délai: Jours 168 et 364
|
Jours 168 et 364
|
|
|
Questionnaire SF-36
Délai: Jours 168 et 364
|
Jours 168 et 364
|
|
|
Évolution des titres d'ANCA (en UI/mL) et corrélation avec les événements cliniques au cours du suivi
Délai: Jour 364
|
Jour 364
|
|
|
Évolution des éosinophiles (en x10^9/L) et corrélation avec les événements cliniques au cours du suivi
Délai: Jour 364
|
Jour 364
|
|
|
Proportion of participants experiencing a relapse
Délai: Day 364
|
EGPA relapse will be defined as worsening or persistence of active disease since the last visit characterized by: a) active vasculitis (BVAS >0); OR b) active asthma symptoms; OR c) active nasal and/or sinus disease, warranting: i) an increased dose of prednisone compared to previous dosage and at least >4 mg/day prednisone total daily dose or equivalent; OR ii) an increased dose or addition of immunosuppressive therapy; OR iii) hospitalisation related to EGPA worsening. A BVAS evaluation will be conducted at the time of a relapse, or as soon as possible afterwards |
Day 364
|
|
Number of relapse during the study period
Délai: Day 364
|
EGPA relapse will be defined as worsening or persistence of active disease since the last visit characterized by: a) active vasculitis (BVAS >0); OR b) active asthma symptoms; OR c) active nasal and/or sinus disease, warranting: i) an increased dose of prednisone compared to previous dosage and at least >4 mg/day prednisone total daily dose or equivalent; OR ii) an increased dose or addition of immunosuppressive therapy; OR iii) hospitalisation related to EGPA worsening. A BVAS evaluation will be conducted at the time of a relapse, or as soon as possible afterwards. |
Day 364
|
|
Number of adverse events that result in the cessation of further injections
Délai: Day 364
|
Number of adverse events is expressed as adverse events according to the CTCAE toxicity grading system per patient-year at days 168 and 364 for the following adverse events combined: death (all causes), grade 2 or higher leukopenia or thrombocytopenia, grade 3 or higher infections, hemorraghic cystitis, malignancies, venous thromboembolic events, hospitalization resulting either from the disease or from a complication due to the study treatment, injection reactions (within 24 hours of injection). |
Day 364
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Loic GUILLEVIN, MD, PhD, Assistance Publique - Hôpitaux de Paris
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies vasculaires
- Maladies cardiovasculaires
- Maladies auto-immunes
- Maladies du système immunitaire
- Maladies de la peau
- Maladies lymphatiques
- Troubles lymphoprolifératifs
- Maladies de la peau, vasculaire
- Vascularite
- Vascularite associée aux anticorps cytoplasmiques anti-neutrophiles
- Granulome
- Vascularite systémique
- Maladies de la peau et du tissu conjonctif
- Maladies hémiques et lymphatiques
- Syndrome de Churg-Strauss
- Composés de soufre
- Produits chimiques organiques
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Acides nucléiques, nucléotides et nucléosides
- Hydrocarbures
- Purines
- Moutards phosphoramides
- Composés de moutarde d'azote
- Composés moutarde
- Hydrocarbures, halogénés
- Phosphoramides
- Composés organophosphores
- Nucléosides
- Thionucléosides
- Mercaptopurine
- Cyclophosphamide
- Azathioprine
- mépolizumab
Autres numéros d'identification d'étude
- D20180135
- 2020-003318-10 (Numéro EudraCT)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .